Subtitle
Proton beam therapy reirradiation for breast cancer: Multi-institutional prospective PCG registry analysis.
Subtitle
Proton beam therapy reirradiation for breast cancer: Multi-institutional prospective PCG registry analysis.
Proto therapy Time
July 2019
Executive summary
This study analyzed 50 patients received PBT reRT for breast cancer in the prospective Proton Collaborative Group (PCG) registry. Median reRT dose was 55.1 Gy and median cumulative dose was 110.6 Gy (70.6-156.8). ReRT included regional nodes in 84% (66% internal mammary node [IMN]).
Grade 3 AEs were experienced by 16% of patients (10% acute, 8% late). All grade 3 AEs occurred in patients receiving IMN reRT (P = 0.08). At 1 year, LRFS was 93%, and OS was 97%. This study concluded that PBT reRT is well tolerated with favorable local control. Toxicity was acceptable despite median cumulative dose > 110 Gy
Key content topics
Top cancer treatments
Other popular content
Proton Therapy Publication
December 2021
Technical insights on the treatment of GI cancers.
Proton Therapy Publication
October 2021
Impact of lymphopenia on the clinical outcomes of esophageal cancer patients
Proton Therapy Publication
October 2021
Acute Hematological Outcomes after Proton and Photon Beam Craniospinal Irradiation in Pediatric Brain Tumors
Proton Therapy Publication
October 2021
Acute Hematological Outcomes in Pediatric Brain Tumors
Proton Therapy Publication
October 2021
Comparison of hypothyroidism and adrenal insufficiency in children with medulloblastoma
Proton Therapy Publication
September 2021
Scoping review of patient selection methods for proton therapy
Proton Therapy Publication
September 2021
Dosimetry, efficacy, safety, and cost-effectiveness of PT for NSCLC
Proton Therapy Publication
September 2021
Reduced diffusion in white matter after radiotherapy with photons and protons
Proton Therapy Publication
September 2021
Particle Radiotherapy for Skull Base Chondrosarcoma
Proton Therapy Publication
September 2021
Assessing concordance between patient-reported and investigator-reported CTCAE after PBT for prostate cancer.
Proton Therapy Publication
September 2021
Current status and application of proton therapy for esophageal cancer
Proton Therapy Publication
September 2021
Bicentric Treatment Outcomes following PT for Non-Myxopapillary High-Grade Spinal Cord Ependymoma in Children
Proton Therapy Publication
September 2021
Identifying individualized risk profiles for radiotherapy-induced lymphopenia
Proton Therapy Publication
September 2021
FLASH proton radiotherapy spares normal epithelial and mesenchymal tissues while preserving sarcoma response
Proton Therapy Publication
August 2021
Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma